Syncom Formulations India Ltd-$
Syncom Formulations India Ltd-$ (SYNCOMF) last traded at ₹17.7, a market capitalisation of ₹1,663 crore, on a P/E of 19.4. Over the past 52 weeks the stock has ranged between ₹10.2 and ₹18.7. Syncom Formulations India Ltd-$ last reported results for the quarter ended Jun 2026, with sales of ₹126 crore and net profit of ₹25 crore. The next scheduled event is a dividend on 23 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Syncom Formulations India Ltd-$ share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Syncom Formulations India Ltd-$ quarterly results
In the quarter ended Jun 2026, sales were ₹126 cr, up 7.7% from ₹117 cr a year earlier. Net profit was ₹25 cr, up 56.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 102 | 128 | 149 | 117 | 122 | 115 | 135 | 126 |
| Expenses | 90 | 113 | 131 | 101 | 103 | 94 | 113 | 99 |
| Operating profit | 12 | 15 | 18 | 16 | 18 | 21 | 22 | 26 |
| OPM % | 12% | 12% | 12% | 14% | 15% | 18% | 16% | 21% |
| Other income | 4 | 4 | 7 | 6 | 5 | 6 | 15 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 15 | 17 | 23 | 20 | 22 | 25 | 34 | 32 |
| Tax % | 25% | 25% | 24% | 22% | 25% | 25% | 25% | 23% |
| Net profit | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 |
| EPS (₹) | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.20 | 0.27 | 0.26 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Syncom Formulations India Ltd-$ annual results
| ₹ crore | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 185 | 216 | 222 | 262 | 463 | 489 | 498 |
| Operating profit | 17 | 20 | 20 | 30 | 54 | 77 | 88 |
| OPM % | 9% | 9% | 9% | 11% | 12% | 16% | 18% |
| Net profit | 11 | 20 | 20 | 25 | 49 | 76 | 86 |
| EPS (₹) | 0.13 | 0.23 | 0.21 | 0.27 | 0.53 | 0.81 | 0.91 |
TTM is the trailing twelve months to the most recent quarter.
Syncom Formulations India Ltd-$ growth and returns
- 10 Years
- 10%
- 5 Years
- %
- 3 Years
- 30%
- TTM
- 0%
- 10 Years
- 22%
- 5 Years
- %
- 3 Years
- 57%
- TTM
- 49%
- 10 Years
- 21%
- 5 Years
- 22%
- 3 Years
- 25%
- 1 Year
- 1%
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 16%
- Last Year
- 20%
Syncom Formulations India Ltd-$ shareholding pattern
Promoters held 50.57% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.35%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% |
| FIIs | 0.10% | 0.13% | 0.11% | 0.41% | 0.10% | 0.26% | 0.21% | 0.35% |
| Public | 49.34% | 49.30% | 49.32% | 49.02% | 49.33% | 49.17% | 49.23% | 49.07% |
| No. of shareholders | 4,69,242 | 4,89,520 | 4,84,529 | 4,71,066 | 4,57,364 | 4,42,280 | 4,31,690 | 4,22,114 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Syncom Formulations India Ltd-$ events
The next scheduled event is a dividend on 23 Sept 2026.
- DividendFinal dividend of Re. 0.10 per share
- DividendDeclaration of final dividend of Rs. 0.10 per share and holding of 38th AGM
- AGM38th Annual General Meeting and remote e-voting arrangements
See the full results calendar for every Indian company reporting in the next 30 days.
Syncom Formulations India Ltd-$ corporate filings
- PURSUANT TO REG 30 SEBI, LODR, WE HEREBY SUBMIT THE PRESS RELEASE ISSUED BY THE COMPANYCompany Updatelow impact
Cruxal's analysis: Syncom Formulations India Ltd has submitted a press release in compliance with Regulation…
Read the full analysis - Submission of Press Clipping Related to extract of Un-Audited Standalone and Consolidated Financial Result for the Quarter ended on 30th June, 2026.Company Updatelow impact
Cruxal's analysis: Syncom Formulations (India) Limited has released its unaudited standalone and…
Read the full analysis - Disclosure under Regulation 30(2) read with Clause 7 of Para A of Schedule /// of the SEBI (LODR) Regulation, 2015: Change in directors, KMP and Senior Management.Company Updatemedium impact
Cruxal's analysis: Syncom Formulations (India) Limited has initiated a significant leadership transition…
Read the full analysis - Corporate Announcement/Information pursuant to Regulation 44 of the SEBI (LODR) Regulation, 2015 regarding providing Remote E-Voting facilities for the 38th Annual General Meeting to be ....Company Updatelow impact
Cruxal's analysis: Syncom Formulations India Ltd has issued a regulatory filing pursuant to Regulation 44 of…
Read the full analysis - Appointment of Cost Auditor and Internal Auditor for the FY 2026-27.Company Updatelow impact
Cruxal's analysis: Syncom Formulations (India) Limited has formally appointed M/s M. Goyal & Co. as Cost…
Read the full analysis - Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon ....Resulthigh impact
Cruxal's analysis: Syncom Formulations (India) Limited reported a robust performance for the quarter ended…
Read the full analysis - We are pleased to inform you that, pursuant to the provision of Regulation 42 of SEBI (LODR) Regulations, 2015 and Section 91 of the Companies Act, 2013 the "Record Date" has been fixed ....Corp. Actionlow impact
Cruxal's analysis: Syncom Formulations (India) Limited has declared a final dividend of 10% (INR 0.10 per…
Read the full analysis - Outcome of the 2/2026-27 Meeting of the Board of Directors of the Company held on Tuesday, 11th August 2026 pursuant to Regulation 30 read with Schedule III(A)(IV) of the SEBI(LODR) Regulations, 2015.Board Meetingmedium impact
Cruxal's analysis: Syncom Formulations (India) Limited has announced a significant management restructuring…
Read the full analysis - Revised Intimation for resignation of Mr. Vijay Shankarlal Bankda Managing Director Under Regulation 30 of SEBI (LODR) Regulations, 2015.Company Updatemedium impact
Cruxal's analysis: Syncom Formulations (India) Limited has formally announced the resignation of its…
Read the full analysis - Intimation for Resignation of Mr. Vijay Shankarlal Bankda Managing Director under Regulation 30 of SEBI (LODR) Regulations, 2015Company Updatemedium impact
Cruxal's analysis: Syncom Formulations (India) Limited has formally announced the resignation of its…
Read the full analysis - Intimation for Resignation of Mr. Rahul Vijay Bankda Chief Financial Officer (CFO) under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Syncom Formulations (India) Limited has formally announced the resignation of its Chief…
Read the full analysis - Intimation for Resignation of Mr. Kedarmal Shankarlal Bankda Whole-Time Director under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirement) Regulation, 2015Company Updatemedium impact
Cruxal's analysis: Syncom Formulations (India) Limited has formally announced the resignation of its Founder…
Read the full analysis - Syncom Formulations India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve we are pleased to ....Board Meetinglow impact
Cruxal's analysis: Syncom Formulations (India) Limited has announced a Board Meeting scheduled for August…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Syncom Formulations India Ltd-$
Cruxal reads every Syncom Formulations India Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.